Tidak mengudara

Berita berkelanjutan · 1 laporan

Novo Nordisk's lawsuit over Eli Lilly GLP-1 ads

Pertama tayang Terbaru tayang

Sedang berkembangPemeriksaan berikutnya : Further court proceedings or a resolution of the case.

Perkembangan terkini

Novo Nordisk has sued Eli Lilly in federal court, alleging its direct-to-consumer GLP-1 drug ads make false and misleading dosing comparisons; Lilly says the ads are truthful. No court ruling, settlement or other resolution is reported, so the case remains open.

Pelacak beritaHari ke-1

1 laporan11 media11 sumber1 video

  • Belum ada peristiwa bertanggal
    1. Pembaruan ke-1Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

    Perkembangan sejauh ini

    1. Pembaruan ke-1

      Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

      A New Jersey federal complaint says Lilly's Zepbound and Mounjaro ads stack the dosing deck against Wegovy and Ozempic. The market they share is reshaping the industry.

      Masih terbuka setelah laporan ini

      • Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
      • How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
      • Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.

    Riwayat

    1. Dibuka1 laporan

    Siapa yang terlibat

    Tempat

    • CopenhagenCopenhagen, Denmark1 laporan
    • IndianapolisIndianapolis, IN, USA1 laporan
    • US District Court for the District of New Jersey50 Walnut St #4015, Newark, NJ 07102, USA1 laporan

    Semua media yang kami baca tentang berita ini

    11 sumber11 media1 video